Introduction
============

Esophageal cancer is the eighth most commonly diagnosed cancer type in the world and the sixth leading cause of cancer-associated cases of mortality ([@b1-ol-0-0-9683]). Esophageal squamous cell carcinoma (ESCC) is the most predominant pathological type of esophageal cancer, accounting for 90% of all esophageal cancer cases in the developing world ([@b2-ol-0-0-9683],[@b3-ol-0-0-9683]). In addition, ESCC has been classified as the most typical esophageal tumor type by the National Health and Family Planning Commission of the People\'s Republic of China ([@b3-ol-0-0-9683]). Although the current standard treatment for patients with ESCC is an esophagectomy and adjuvant chemoradiation, the overall 5-year survival rate is only approximately 17% due to the risks associated with this treatment ([@b2-ol-0-0-9683]). In addition, the prognosis for patients with an equivalent stage of ESCC varies markedly ([@b4-ol-0-0-9683]). A selection of serum biomarkers has previously been identified to predict the survival rate of patients with ESCC; however, the limited sensitivity and specificity of these markers, including squamous cell carcinoma antigen, cytokeratin 19 fragments and carcinoembryonic antigen, have restricted their clinical use ([@b5-ol-0-0-9683]--[@b7-ol-0-0-9683]). Therefore, novel predictive biomarkers, which may also promote targeted therapy for ESCC, are required.

Abdominal obesity and lipid levels are closely associated with the occurrence of esophageal cancer and several other tumor types ([@b8-ol-0-0-9683]--[@b11-ol-0-0-9683]), and high levels of lipids in serum and cell membranes are associated with the prognosis of multiple tumor types ([@b12-ol-0-0-9683]--[@b14-ol-0-0-9683]). A previous study demonstrated that total cholesterol (TC) is a good predictive marker for grading tumor regression in patients with locally advanced colorectal cancers previously treated with neoadjuvant chemoradiotherapy ([@b15-ol-0-0-9683]). High-density lipoprotein (HDL) is a risk factor and a prognostic factor in prostate cancer, and a decrease in HDL levels is associated with poor survival among patients with non-small-cell lung carcinoma ([@b6-ol-0-0-9683],[@b13-ol-0-0-9683]). Additionally, apolipoprotein A1, a major component of HDL, is considered to be a predictive biomarker of survival rate in patients with ESCC ([@b14-ol-0-0-9683]). Low-density lipoprotein (LDL) has also been implicated in ESCC ([@b14-ol-0-0-9683]), but a negative association has been reported in other studies ([@b16-ol-0-0-9683]). Regardless, the major receptor of LDL, lectin-like oxidized low-density lipoprotein (LOX-1) is a verified significant prognostic factor for multiple cancer types ([@b17-ol-0-0-9683]--[@b20-ol-0-0-9683]). To date, a few studies have focused on the prognostic role of triglyceride (TG) levels in breast cancer ([@b21-ol-0-0-9683]).

To clarify the prognostic value of lipid profiles in ESCC, the current study retrospectively investigated preoperative TC, HDL, LDL and TG levels in 242 patients with ESCC and analyzed associations between these levels and overall survival (OS). Additionally, the current study performed *in vitro* experiments to preliminarily explore a possible mechanism based on these associations.

Materials and methods
=====================

### Study patients

A total of 250 eligible patients with ESCC who underwent an esophagectomy at Shandong Cancer Hospital (Jinan, China) between April 2012 and October 2014 were included in the current study. The inclusion criteria were as follows: i) Patients were previously diagnosed with ESCC and received radical surgery; ii) TC, TG, HDL and LDL levels were examined 2--5 days prior to surgery between 6:00 and 8:00 a.m. using a Modular p800 analyzer (Roche Diagnostics, Basel, Switzerland); and iii) no drugs known to affect lipids, including statins, were taken by the patients. Exclusion criteria were as follows: i) History of another cancer type; ii) diabetes or another endocrine or metabolic disease that may influence serum lipid levels; and iii) cachexia \[body mass index (BMI) \<20 kg/m^2^\].

### Follow-up assessment

Follow-up assessments were performed annually by telephone interviews and review of medical records. This was performed every 2 months for patients with evidence of distant metastasis and local recurrence. The last follow-up was completed in October 2016. The endpoint of the current study was OS, which was defined as the time interval between diagnosis and mortality or the last follow-up. Survivors were defined as alive at the time of the last follow-up, whereas non-survivors were defined as having died at any time during the study. Tumor and clinical characteristics of the patients, including age, sex, Pathological N-staging status (pT status), Pathological N-staging status (pN status), grade and histological type, were obtained from medical records and pathology reports.

The current study was approved by the Institutional Review Board of Shandong Cancer Hospital. Informed consent and survival status were verified through direct telecommunication with the patients or their families.

### Cell culture

Esophageal cancer cell lines TE-1 and ECa109 were obtained from the Cell Bank of the Chinese Academy of Sciences (Institute of Shanghai Cell Biology and Chinese Type Culture Collection, Shanghai, China). ECa109 cells were grown in RPMI-1640 and TE-1 cells were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum (all from Hyclone; GE Healthcare, Logan, UT, USA). All cells were grown at 37°C in humidified air containing 5% CO~2~.

### Cell viability detection via the Cell Counting Kit-8 (CCK8) assay and cell cycle analysis by flow cytometry

TE-1 and ECa109 cells were seeded in 96-well plates at 3.0×10^3^/well and maintained for 24 h until attachment at 37°C in a humidified, 5% CO~2~, 95% air atmosphere. The cells were then starved with serum-free medium for 4 h and incubated with various concentrations of LDL (0, 10, 50, 100, 200 and 400 µg/ml; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 24, 48 and 72 h at 37°C in a humidified, 5% CO~2~. To determine the effects of LDL, TE-1 and ECa109 cell viability was measured using the CCK8 assay according to the manufacturer\'s protocol (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and the cell cycle was detected by Propidium lodide (PI)/RNase Staining Buffer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed by flow cytometry with Modfit LT 4.0 (Verity Software House, Topsham, ME, USA).

### Statistical analysis

Statistical analyses were performed with SPSS 21.0 software (IBM Corp., Armonk, NY, USA). Serum lipid levels were expressed as the mean ± standard deviation. Univariate and multivariate analyses were performed using Kaplan-Meier and Cox proportional hazards regression models to determine associations between OS, the clinical parameters and the TC, HDL, LDL and TG levels. The hazard ratio (HR) was reported as the relative risk with 95% confidence intervals. Associations between the serum lipids and clinical characteristics were determined with the χ^2^ test or univariate analysis. Survival curves were plotted on the basis of the aforementioned results and the curves were compared using the log-rank test. All P-values were two-sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

In the current retrospective study, follow-up of 242 patients with ESCC was completed with a success rate of 96.8% (242/250; 3 patients refused to provide information and communication was lost with 5 patients). The 242 patients included 190 (78.5%) males and 52 (21.5%) females, with a median age of 61 years (range, 35--80 years). The disease characteristics were as follows: 20 (8.3%) patients had upper thoracic esophageal cancer, 128 (52.9%) had middle thoracic esophageal cancer and 94 (38.8%) had low thoracic esophageal cancer. Histologically well-differentiated disease, moderately differentiated disease and poorly differentiated disease were identified in 60 (24.8%), 122 (50.4%) and 60 (24.8%) patients, respectively. Among the patients, 19 (7.8%) had stage T1 disease, 28 (11.6%) had stage T2 disease, 158 (65.3%) had stage T3 disease and 37 (15.3%) had stage T4 disease. Regarding staging, 110 (45.5%) patients demonstrated stage N0 disease, 94 (38.8%) stage N1 disease, 29 (12.0%) stage N2 disease and 9 (3.7%) N3 disease ([Table I](#tI-ol-0-0-9683){ref-type="table"}).

The mean values of serum lipid levels prior to therapy were as follows: TC=4.72±0.89 mmol/l, TG=1.10±0.57 mmol/l, LDL=2.63±0.56 mmol/l and HDL=1.30±0.38 mmol/l ([Table II](#tII-ol-0-0-9683){ref-type="table"}).

### LDL, pT status, pN status and histological differentiation are independent prognostic factors in patients with ESCC

The χ^2^ test, Kaplan-Meier analysis and Cox regression model were applied to characterize the association between prognosis and serum lipid levels or clinical parameters, including age, sex, tumor location, histological differentiation, pT status and pN status, in patients with ESCC ([Table I](#tI-ol-0-0-9683){ref-type="table"}). Univariate survival analysis revealed significant associations between poor survival and HDL (χ^2^=3.914, P=0.048), LDL (χ^2^=5.454, P=0.020), pT status (T1-2 vs. T3-4; χ^2^=27.277, P=0.001), pN status (N0 vs. N1-3; χ^2^=71.184, P=0.001) and histological differentiation (χ^2^=12.615, P=0.002), whereas the other clinical features investigated in the current study demonstrated no association with OS. Multivariate survival analysis was performed to clarify the independent prognostic values of these five factors, with LDL (HR=2.164, P=0.005), histological differentiation (HR=4.083, P=0.002), pT status (HR=1.714, P=0.001) and pN status (HR=1.966, P=0.001) demonstrating an association with ESCC prognosis. Survival curves were then generated based on these results. The 3-year survival rate of patients with ESCC with lower LDL levels (≤3.12 mmol/l) was 34.7%, compared with 15.8% for patients with higher LDL levels (\>3.12 mmol/l; [Fig. 1A](#f1-ol-0-0-9683){ref-type="fig"}). Additionally, a higher pT status and pN status were associated with a poor 3-year survival rate in patients with ESCC (T1-2 vs. T3-4, 45.5 vs. 27.1%; N0 vs. N1-3, 50.9 vs. 13.8%; [Fig. 1B and C](#f1-ol-0-0-9683){ref-type="fig"}), as was histological differentiation (high-differentiated disease vs. low vs. moderate differentiation, 56.7% vs. 24.6% vs. 23.2%; [Fig. 1D](#f1-ol-0-0-9683){ref-type="fig"}). Therefore, the current study identified that pre-therapy serum LDL level may be a significant prognostic factor for patients with ESCC.

### Associations between LDL levels and other clinical characteristics

The observed associations between different levels of LDL and other clinical features are presented in [Table III](#tIII-ol-0-0-9683){ref-type="table"}. Statistical analysis identified that the LDL level was significantly associated with sex (P=0.001), tumor location (P=0.004) and pN status (P=0.007). However, no significant associations were evident between the LDL level and the other parameters investigated in the current study.

### Effect of LDL on cell proliferation

As demonstrated in [Fig. 2A](#f2-ol-0-0-9683){ref-type="fig"}, TE-1 cell proliferation was promoted by LDL; the proliferation level increased as the LDL treatment time increased and as the LDL concentration increased (P\<0.05). However, the proliferation level declined when the LDL concentration exceeded 200 µg/ml. This finding indicated that an appropriate LDL concentration may promote esophageal carcinoma cell growth. TE-1 cells exhibited the largest proliferation efficiency when treated with 200 µg/ml LDL for 72 h. The growth characteristics of ECa109 cells were equivalent to those of TE-1 cells ([Fig. 2B](#f2-ol-0-0-9683){ref-type="fig"}).

### Effect of LDL on cell cycle distribution

The cell cycle was also analyzed to confirm the promoting effect of LDL on esophageal carcinoma cell proliferation. TE-1 and ECa109 cells were incubated with different concentrations of LDL (0, 50, 100 and 200 µg/ml) for 72 h and then collected for cell cycle analysis. As demonstrated in [Fig. 3](#f3-ol-0-0-9683){ref-type="fig"}, the percentage of G1-phase TE-1 cells decreased from 73.05 to 40.08% in response to LDL, with a corresponding increase in the total proportion of S and G2-phase cells from 26.95 to 59.92%. These data indicated that proliferation was induced by LDL in TE-1 cells. Similar results were obtained with ECa109 cells, whereby the G1-phase proportion decreased from 63.91 to 51.83% and the total proportion of S and G2 phase cells increased from 36.09 to 48.17% in response to LDL ([Fig. 4](#f4-ol-0-0-9683){ref-type="fig"}).

Discussion
==========

The preoperative serum lipid levels of patients with ESCC were evaluated in the current study. Operable patients were selected because they had well-defined disease stages and good nutrition statuses, which may avoid abnormal blood lipid levels caused by dystrophia. In addition, BMI and serum albumin levels were comparable between the higher LDL group and lower LDL group (data not shown). Therefore, in the current study, preoperative serum lipid levels were considered to be independent of nutritional status. The number of male patients was more than three times that of female patients (190 vs. 52). In China, there is a significant sex difference in the incidence of esophageal cancer and the proportion of men and women included in the current study is consistent with the incidence ([@b22-ol-0-0-9683]). This predominance may be because abdominal adiposity is more common in males; abdominal adiposity increases intragastric pressure and relaxes the lower esophageal sphincter, which leads to acid reflux ([@b23-ol-0-0-9683]). Furthermore, males are more likely to consume alcohol and smoke cigarettes, and these factors have been suggested as the underlying reason for the higher number of males with ESCC relative to females ([@b24-ol-0-0-9683]).

The results of the current study demonstrate that high LDL (\>3.12 mmol/l) is positively associated with a short OS time, as are other parameters, including pT status, pN status and histological differentiation. This association may be caused by increased lymphatic metastasis. However no significant association was identified between serum LDL level and pN status in a similar study ([@b25-ol-0-0-9683]). There may be several reasons for this; firstly, retrospective studies are prone to bias and may explain why the current study and the previous study draw different conclusions. Secondly, the research data used in the current study and the previous study were collected between 2012--2014 and 2007--2008, respectively, but both datasets are limited. In addition, the number of patients in both studies was more than 200, this facilitates preliminary results to be obtained but a larger sample size is required for further confirmation. The authors of both studies are currently preparing to collaborate and analyze a larger sample with joint multi-centric data in the hope of obtaining more convincing results. Lastly, different patient groups were selected in the two different studies; the proportion of patients with T3 and T4 stage disease in the current study was as high as 80.4%, whereas this number was 61.7% in the previous study. Differences in the stage of ESCC may affect the nutritional status of patients and cause a decrease in blood lipid levels.

Several previous studies have also suggested there is a significant association between LDL levels and cancer prognosis. Zhou *et al* ([@b26-ol-0-0-9683]) demonstrated that LDL is a prognostic index for the survival of patients with small-cell lung cancer and Rodrigues *et al* ([@b27-ol-0-0-9683]) indicated that the LDL level is associated with disease-free survival in patients with breast cancer. In patients with prostate cancer, preoperative LDL cholesterol is an independent predictor of recurrence ([@b28-ol-0-0-9683]) and LDL is also an independent prognostic factor for patients with colorectal cancer ([@b29-ol-0-0-9683]). Additionally, in the current study, the LDL level demonstrated an independent association with the pN status of ESCC, which was consistent with the research conclusion of the current study ([Table III](#tIII-ol-0-0-9683){ref-type="table"}). Sako *et al* ([@b30-ol-0-0-9683]) also identified that hyperlipidemia is a risk factor for lymphatic metastasis in superficial esophageal carcinoma, which supports the conclusion made by the current study.

Several years ago, multiple studies supported the view that exogenous LDL promoted the proliferation of breast cancer and colon adenocarcinoma cells ([@b31-ol-0-0-9683],[@b32-ol-0-0-9683]). The results of the current study, which are based on cell viability assays and cell cycle analysis, support a similar conclusion in esophageal cancer cells. To the best of our knowledge, the current study is the first to demonstrate that LDL enhances the growth rate of esophageal cancer cells *in vitro*. This observation may be attributed to the possible involvement of the LDL receptor-related protein 1 (LRP1) in regulating cancer cell survival and metastatic potential, which occurs through the ability of LDL to promote cancer cell proliferation and differentiation ([@b30-ol-0-0-9683],[@b33-ol-0-0-9683]). This hypothesis requires a more detailed investigation.

Although the findings of the current study provide evidence of a preliminary mechanism through our *in vitro* analysis, the intrinsic mechanism by which LDL promotes cell development is unclear. Several interesting studies have suggested that many factors may explain the findings to date. Firstly, migration and invasion of tumor cells is partially dependent on exogenous LDL cholesterol and is possibly driven through LDL-related receptors ([@b34-ol-0-0-9683],[@b35-ol-0-0-9683]). LOX-1 may facilitate the proliferation of gastric cancer cells by driving the epithelial-mesenchymal transition and phosphoinositide 3-kinase/Akt/glycogen synthase kinase β activation ([@b34-ol-0-0-9683]). Additionally, low-density lipoprotein receptor serves an important role in tumor cancer growth and invasion by regulating nuclear factor κ-light-chain enhancer of activated B cells signaling, and this serves as a prognostic index in patients with small cell lung cancer ([@b26-ol-0-0-9683],[@b36-ol-0-0-9683]). Furthermore, LRP1 may contribute to the ability of cancer cells to form large metastases via increased expression of vascular endothelial cell growth factor (VEGF) and reduced cell death in response to hypoxia ([@b33-ol-0-0-9683]); tumor invasion is promoted via stimulation of the extracellular signal-regulated kinase pathway and inhibition of the c-Jun N-terminal kinase pathway ([@b35-ol-0-0-9683]).

Similar to the study by Montel *et al* ([@b33-ol-0-0-9683]), the addition of LDL cholesterol may induce activation of microvascular endothelial cells, which facilitates lymph node metastases of colon cancer cells ([@b31-ol-0-0-9683]). Additionally, Lu *et al* ([@b37-ol-0-0-9683]) demonstrated that L5, a cytokine through which LDL induces endothelial apoptosis, increases secretion of an angiogenic factor, amphiregulin, by breast cancer cells and promotes progression and metastasis ([@b37-ol-0-0-9683]). Other inflammatory cytokines, including L1 and tumor necrosis factor, can also promote progression and metastasis, which may induce hyper-adhesion to vascular endothelial cells and augment tumor arrest and metastasis ([@b38-ol-0-0-9683],[@b39-ol-0-0-9683]).

Furthermore, suppressive effects on the function of immune cells may be another mechanism through which a high LDL level enhances tumor metastasis. LRP1-deficient myeloid cells may allow tumor-associated macrophages to provide increased amounts of VEGF to a tumor ([@b40-ol-0-0-9683]). McCarthy *et al* ([@b41-ol-0-0-9683]) reported that a high LDL level inhibits T cell proliferation and macrophage tumoricidal activity may be decreased by a high-fat diet in mice ([@b42-ol-0-0-9683]).

Based on these speculations and the results of the current study, it can be proposed that LDL is a prognostic factor in patients with ESCC because it promotes lymphatic metastasis. Although the intrinsic mechanism is unclear, a high level of LDL has an apparent role in promoting growth of TE-1 and ECa109 esophageal cancer cells. However, the current study has several limitations. Firstly, this was a retrospective study and not a prospective study. Additionally, patients from only one institution were recruited and only 242 patients were included. Future studies may involve more patients from multiple centers and the detailed mechanism of the effect of LDL on esophageal carcinoma cells may be investigated further

In summary, the LDL level is an adverse prognostic factor for ESCC. Additionally, LDL is an economical and convenient biomarker that may support clinical needs. Furthermore, to the best of our knowledge, the current study is the first to hypothesize that a high LDL level is associated with poor OS because LDL promotes lymphatic metastasis and this hypothesis has been partially confirmed *in vitro*. A more detailed mechanism is required to be investigated in future studies.
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![Prognostic significance of LDL and other clinical features in esophageal squamous cell carcinoma. (A) High LDL, (B) pT status, (C) pN status and (D) low differentiation were poor prognostic factors according to Cox survival curves. LDL, low-density lipoprotein; OS, overall survival.](ol-17-01-1053-g00){#f1-ol-0-0-9683}

![Effect of LDL on TE-1 and ECa109 esophageal cancer cell viability. Cells were incubated with various concentrations of LDL (0--400 µg/ml) for 24 h (black line), 48 h (red line) and 72 h (blue line). (A) The TE-1 proliferation rate increased with the treatment time and with a concentration \<200 µg/ml; the proliferation rate decreased with LDL concentrations between 200 and 400 µg/ml (\*P\<0.05 vs. 24 h; \*P\<0.05 vs. 48 h; \*\*P\<0.01 vs. 72 h). (B) Similar results were obtained using ECa109 cells (\*P\<0.05 vs. 24 h; \*P\<0.05 vs. 48 h; \*\*P\<0.01 vs. 72 h). LDL, low-density lipoprotein.](ol-17-01-1053-g01){#f2-ol-0-0-9683}

![Effect of LDL on the TE-1 cell cycle distribution. Cells were incubated with various concentrations of LDL; (A) 0 µg/ml, (B) 50 µg/ml, (C) 100 µg/ml and (D) 200 µg/ml for 72 h and the percentage of cells in each phase of the cell cycle was determined by flow cytometry. LDL, low-density lipoprotein; dip, diploid.](ol-17-01-1053-g02){#f3-ol-0-0-9683}

![Effect of LDL on the ECa109 cell cycle distribution. Cells were incubated with various concentrations of LDL; (A) 0 µg/ml, (B) 50 µg/ml, (C) 100 µg/ml and (D) 200 µg/ml for 72 h and the percentage of cells in each phase of the cell cycle was determined by flow cytometry. LDL, low-density lipoprotein; dip, diploid.](ol-17-01-1053-g03){#f4-ol-0-0-9683}

###### 

Univariate and multivariate analysis for overall survival in patients with esophageal squamous cell carcinoma.

                                       Univariate analysis   Multivariate analysis                   
  ------------------------------ ----- --------------------- ----------------------- ------- ------- -------
  Age                                  0.024                 0.876                                   
    \<60                         114                                                                 
    ≥60                          128                                                                 
  Sex                                  3.617                 0.057                                   
    Male                         190                                                                 
    Female                       52                                                                  
  Tumor location                       5.745                 0.056                                   
    Upper                        20                                                                  
    Middle                       128                                                                 
    Lower                        94                                                                  
  Histological differentiation         12.615                0.002                   1.407   4.083   0.002
    Well                         60                                                                  
    Moderate                     122                                                                 
    Low                          60                                                                  
  pT status                            27.277                0.001                   0.539   1.714   0.001
    T1                           19                                                                  
    T2                           28                                                                  
    T3                           158                                                                 
    T4                           37                                                                  
  pN status                            71.184                0.001                   0.676   1.966   0.001
    N0                           110                                                                 
    N1                           94                                                                  
    N2                           29                                                                  
    N3                           9                                                                   
  TC, mmol/l                           0.878                 0.349                                   
    \>5.2                        72                                                                  
    ≤5.2                         170                                                                 
  TG, mmol/l                           2.843                 0.096                                   
    \>1.7                        32                                                                  
    ≤1.7                         210                                                                 
  LDL, mmol/l                          5.454                 0.02                    0.722   2.164   0.005
    \>3.12                       44                                                                  
    ≤3.12                        198                                                                 
  HDL, mmol/l                          3.914                 0.048                   0.063   0.939   0.757
    \>1.42                       74                                                                  
    ≤1.42                        168                                                                 

HR, hazard ratio; TC, total cholesterol; TG, triglyceride; LC, lipoprotein cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; n, number; β, β-coefficient; pT status, Pathological T-staging status; pT status, Pathological N-staging status.

###### 

Lipid levels and association with overall survival.

  Serum lipid   Min, mmol/l   Max, mmol/l   Mean ± SD, mmol/l   HR      P-value
  ------------- ------------- ------------- ------------------- ------- ---------
  TC            2.84          7.12          4.72±0.89           1.096   0.319
  TG            0.49          5.16          1.10±0.57           1.057   0.724
  LDL           1.63          5.16          2.63±0.56           2.164   0.005
  HDL           0.57          2.94          1.30±0.38           0.939   0.757

TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; min, minimum; max, maximum; HR, hazard ratio; SD, standard deviation.

###### 

Clinical patient characteristics according to the LDL level.

  Characteristic   LDL \>3.12 mmol/l, n (n=44)   LDL ≤3.12 mmol/l, n (n=198)   χ^2^     P-value
  ---------------- ----------------------------- ----------------------------- -------- ---------
  Age                                                                          1.4114   0.234
    \<60           16                            94                                     
    ≥60            28                            104                                    
  Sex                                                                          25.11    0.001
    Male           20                            165                                    
    Female         22                            33                                     
  Tumor location                                                               10.90    0.004
    Upper          10                            11                                     
    Middle         20                            109                                    
    Lower          14                            78                                     
  HD                                                                           0.506    0.777
    Well           10                            54                                     
    Moderate       22                            99                                     
    Low            12                            45                                     
  pT status                                                                    5.566    0.135
    T1-2           11                            36                                     
    T3-4           33                            162                                    
  pN status                                                                    12.156   0.007
    N0             18                            87                                     
    N1-3           26                            111                                    

LDL, low-density lipoprotein; HD, Histological differentiation; n, number; pT status, Pathological T-staging status; pT status, Pathological N-staging status.
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